The FDA is expected to decide on treatments for acquired hypothalamic obesity, dry eye disease, primary biliary cholangitis, psoriatic arthritis, and severe leukocyte adhesion deficiency-I.
Oveporexton is designed to promote wakefulness and reduce abnormal REM-sleep-like phenomena, including cataplexy, in patients with NT1.
FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in ...
NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...
14hon MSNOpinion
Opinion: A legislative win at last, but delays were costly for children with rare diseases
Congress has finally acted, but the legislation did not come soon enough for many.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results